DALLAS, November 16, 2020-Patients with transient ischemic attack (TIA) or mild ischemic stroke (also known as warning stroke) and accumulates plaque in arteries treated with the new blood thinner ticagrelor plus, the American Heart Association’s 2020 Science The latest study published in the session found that aspirin was 27% less likely to have another stroke within 30 days. The Virtual Conference runs from Friday, November 13th to Tuesday, November 17th, 2020 and is the premier global exchange for the latest scientific advances, research and evidence-based clinical practice updates in cardiovascular science for healthcare worldwide. The manuscript of this study is published concurrently today in Stroke, the journal of the American Heart Association.
In the THALES trial, sub-analysis of acute stroke or transient IscHemic seizures treated with Ticagrelor and Aspirin for the prevention of stroke and death, ticagrelor benefited more patients with plaque buildup (atherosclerosis) in the arteries than those with stroke. Another cause. These findings, combined with previous studies, show that the combination of ticagrelor and aspirin is more effective than both drugs alone.
“In our opinion, health care professionals should now consider both ticagrelor and aspirin to prevent another stroke in patients experiencing stroke warnings. Our study shows that using this new therapy is the first symptom to be used. It is effective to treat the patient within 24 hours afterwards, especially the cause of stroke, which is the cause of plaque buildup in the arteries in Paris, France.
Of the more than 11,000 participants originally enrolled in the multinational THALES clinical trial (conducted in 2018 and 2019), about 1 in 2,351 had plaque buildup in their arteries. Researchers randomly classified these patients into two groups (aspirin and ticagrelor, or aspirin alone) to determine if the drug combination was a more effective treatment than the drug alone.
After an initial dose of 180 mg, the researchers added 90 mg of ticagrelor twice a day to 75-100 mg of daily aspirin for a month, with a 27% reduction in the risk of another stroke or death among these patients.
The THALES trial is a randomized, placebo-controlled, double-blind, international, multi-site study. It is currently in phase 3 and started in January 2018.
Co-authors are Hans Denison, MD, Ph.D. Scott. R. Evans, Ph. D.; Anders Himmelmann, MD, Ph.D.; Stegan James, MD, Ph.D.; Mikael Knuttson, Ph.D.; Per Ladenvall, MD, Ph.D.; Carlos Molina, MD, Ph.D.; Yongjun Wang, MD; Claiborne Johnston, MD, Ph.D. Author disclosure is in the abstract. This study was funded by AstraZeneca.
Note: Session: LBS.07-Random Test-Brain, Kidney and Heart
Multimedia is available in the right column of the release link https:/.
Learn more about TIA
Understanding your options when taking aspirin and other antiplatelet drugs
Follow us on Twitter for more news from AHA Scientific Sessions 2020. Huh
The statements and conclusions of the studies presented at the American Heart Association’s scientific conference are entirely those of the authors of the study and do not necessarily reflect the association’s policy or position. The association makes no representations or warranties as to its accuracy or reliability. Associations primarily receive funds from individuals. Foundations and businesses (including pharmaceuticals, device manufacturers, and other companies) also make donations and fund certain association programs and events. The association has a strict policy to ensure that these relationships do not affect scientific content. Revenues for pharmaceutical and biotech companies, device manufacturers and health insurance providers can be found here, and full financial information for the association can be found here.
About the American Heart Association
The American Heart Association is the power to lead the world for longer and healthier lives. Through nearly a century of lifesaving efforts, the Dallas-based association is committed to ensuring equal health for all. We are a trusted source to help people improve their heart health, brain health and well-being. We work with countless organizations and millions of volunteers to fund innovative research, advocate stronger public health policies, and share life-saving resources and information. Connect with us at heart.org, Facebook, Twitter or by calling 1-800-AHA-USA1.
disclaimer: AAAS and EurekAlert! EurekAlert is not responsible for the accuracy of any press releases posted on EurekAlert! Donate to an institution or use the information through the EurekAlert system.